Biggest News Aggregation in the World
๐Ÿ“ฐ Leukemia News

Page 158 - Leukemia News Today

Fast, Ad-Free News Updates

Stay updated with breaking news from Leukemia. Real-time updates on events, politics, business and more.

Stay Updated with Latest News

Get breaking news updates delivered to your inbox

Browse All News โ†’

Research reveals how highly proliferative leukemia cells turn into normal harmless ones

A new researchโ€‹โ€‹ describes how highly proliferative leukemia cells end up becoming normal cells that no longer multiply, by changing the chemical modifications -the so-called epigenetics- of a type of its genetic material: the messenger RNA.
Comunidad Autonoma De Cataluna Alberto Bueno Costa Manel Esteller Emily Henderson University Of Barcelona Josep Carreras Leukaemia Research Institute

Aptevo Therapeutics Announces New Preliminary Remission Data on Four Additional Patients Enrolled in On-going APVO436 Dose Expansion Phase 1b Trial for the Treatment of Acute Myeloid Leukemia

Cohort 1 Combination Therapy Arm Shows 36% Remission Rate Among Response-evaluable Patients Treated to DateCohort 3 Monotherapy Patient Achieved Bone Marrow Complete RemissionCompany Also Reports Myelodysplastic
Miriam Weber Miller Dirk Huebner Exchange Commission Aptevo Therapeutics Inc Therapy Arm Shows Patient Achieved Bone Marrow Complete

Three-drug therapy with autologous stem cell transplant improves progression-free survival for multiple myeloma patients

Patients with multiple myeloma who have been treated with a three-drug combination therapy have a growing number of choices for subsequent treatment. Results of a new study led by researchers at Dana-Farber Cancer Institute can help patients and their physicians weigh benefits and risks of each option.
United States Dana Farber Kennethc Anderson Nikhil Munshi Emily Henderson Paulg Richardson National Cancer Institute

Promising results of combination treatment for acute myeloid leukemia to be presented at ASCO 2022

On Tuesday, June 7, Eunice Wang, MD, Chief of Leukemia at Roswell Park Comprehensive Cancer Center, will present the long-term results of a phase 2 clinical trial combining crenolanib, a second-generation FLT3 inhibitor, with standard intensive chemotherapy for treatment of adults with newly diagnosed FLT3-mutant acute myeloid leukemia (AML).
United States Roswell Park Eunice Wang Emily Henderson American Society Of Clinical Oncology Leukemia At Roswell Park Comprehensive Cancer Center

Explore More Categories

World News India News Business Technology Sports Entertainment Health Science